Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,620 matching trials from the live ClinicalTrials.gov search.
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab, bevacizumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
59
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more
Completed Not applicable Interventional Results available

RETeval Study for Diabetic Retinopathy

NCT01950663
Conditions
Diabetic Retinopathy
Interventions
RETeval
Device
Lead sponsor
Inoveon Corporation
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Decatur, Georgia • Oklahoma City, Oklahoma
Conditions
Central Nervous System/Leptomeningeal Neoplasms
Interventions
131I-omburtamab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO

NCT01692938
Conditions
Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
Interventions
Not listed
Lead sponsor
Optos, PLC
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
TG100801
Drug
Lead sponsor
TargeGen
Industry
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Tucson, Arizona • Beverly Hills, California • Winter Haven, Florida + 5 more
Conditions
Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
Interventions
Intravitreal aflibercept injection, Sham control
Drug · Other
Lead sponsor
M. Ali Khan, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting No phase listed Observational

Gyrate Atrophy Ocular and Systemic Study

NCT05312736
Conditions
Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy, Ornithine-δ-aminotransferase, OAT, Chorioretinal Degeneration
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Conditions
Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions
ENV-101 (taladegib)
Drug
Lead sponsor
Endeavor Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
Conditions
Age-related Macular Degeneration
Interventions
RetnaGene AMD LDT
Device
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Conditions
Neovascular (Wet) Age-Related Macular Degeneration
Interventions
EYC-0305
Biological
Lead sponsor
Eyconis INC.
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Beverly Hills, California • Modesto, California • Wake Forest, North Carolina + 4 more
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
99
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
Completed No phase listed Observational

Screening for NEI Clinical Studies

NCT00001734
Conditions
Conjunctivitis, Iritis, Keratitis, Retinitis, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Phase 3 Interventional

Fenofibrate for Prevention of DR Worsening

NCT04661358
Conditions
Diabetic Retinopathy
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 80 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
66
States / cities
Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more
Completed No phase listed Observational

Comparing 3 Imaging Systems

NCT05022615
Conditions
Diabetic Retinopathy
Interventions
Topcon Camera, Optos Camera, Clarus Camera
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Microvascular Disease, Retinal Disease
Interventions
XyCAM CRE Imaging
Device
Lead sponsor
Stuart Terry Eye Associates
Other
Eligibility
21 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Macular Degeneration, Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
10 Years to 100 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Geographic Atrophy, Dry Age-Related Macular Degeneration
Interventions
Avacincaptad Pegol, Sham
Drug · Other
Lead sponsor
IVERIC bio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 48 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alpha MSH in Ocular Disease

NCT03451578
Conditions
Advanced Dry Macular Degeneration
Interventions
Alpha MSH assay
Device
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
1.0mg Luminate®, 2.0mg Luminate®, 3.0mg Luminate®, Balanced Salt Solution for intravitreal injection in 0.10cc
Drug · Other
Lead sponsor
Allegro Ophthalmics, LLC
Industry
Eligibility
45 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Mountain View, California • Orange, California • New London, Connecticut + 9 more
Conditions
Macular Degeneration
Interventions
VEGF Trap Eye
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
33
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more
Conditions
Diabetic Retinopathy
Interventions
Online Survey
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Retinitis Pigmentosa
Interventions
Lutein (10 or 30 mg/day) capsules
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
Not listed
Timeline
2001 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Ranibizumab, Peripheral Laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • New York, New York